YOLFTbeta
PureTech Health plc

PureTech Health plc

PRTC · LSE · Healthcare / Biotechnology

120.40GBX-3.60 (-2.90%)

Price History

Full chart

Market Stats

Previous Close124.00
Open121.00
Day Range120.00 – 125.10
52-Week Range106.77 – 143.60
Volume122.15K
Market Cap263.81M
P/E (TTM)0.00
Forward P/E14.66
EPS0.00
Dividend Yield0.00%
Beta0.81
50-Day Avg119.01
200-Day Avg124.99

About

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Robert Lyne J.D., L.L.B.
  • Employees90
  • Headquarters6 Tide Street, Boston, MA, United States, 02210, UK
  • Websitehttps://www.puretechhealth.com

Leadership

  • Mr. Robert Lyne J.D., L.L.B.CEO & Director · b. 1983
  • Dr. Robert S. Langer Jr., Ph.D., ScDCo-Founder & Non-Executive Director · b. 1949
  • Dr. Eric Elenko Ph.D.Co-Founder & President · b. 1973
  • Dr. David R. Elmaleh Ph.D.Co-Founder & Senior Advisor · b. 1948
  • Ms. Lauren A. White M.B.A.Chief Financial Officer · b. 1979
  • Mr. Charles Sherwood III, J.D., Ph.D.COO, General Counsel & Company Secretary
  • Mr. Michael Inbar CPA, M.B.A.Chief Accounting Officer
  • Ms. Allison Mead TalbotSenior VP of Communications & Head of Investor Relations
  • Ms. Aleksandra Filipovic M.D., Ph.D.Head of Oncology
  • Ms. Joy Bauer M.S., RDNChief Nutrition Officer

Financials

Income Statement

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue7.93M7.02M2.01M11.74M4.43M650.00K16.37M8.69M8.34M9.98M2.09M750.00K4.32M4.76M
Growth (%)--11.51%-71.33%+483.50%-62.26%-85.33%+2418.62%-46.93%-3.99%+19.64%-79.06%-64.11%+475.33%+10.24%
Cost of Revenue-00-88.00K41.20M71.03M77.40M85.85M-110.47M152.43M93.66M2.79M3.42M
Gross Profit7.93M7.02M2.01M11.83M-36.77M-70.39M-61.03M-77.16M8.34M-100.49M-136.81M-92.91M4.32M1.34M
Gross Margin100.00%100.00%100.00%100.75%-829.93%-10828.46%-372.80%-888.12%100.00%-1007.03%-6546.17%-12387.33%100.00%28.14%
Operating Expense17.32M10.75M19.46M55.47M37.16M45.03M42.99M58.24M127.87M49.79M60.99M53.29M140.41M101.93M
Operating Income-9.38M-3.73M-17.45M-43.64M-73.93M-115.42M-104.02M-135.40M-119.53M-150.28M-197.81M-146.20M-136.09M-100.59M
Operating Margin-118.32%-53.16%-867.05%-371.74%-1668.45%-17756.92%-635.39%-1558.46%-1433.05%-1505.98%-9464.45%-19493.20%-3154.00%-2114.72%
EBITDA-9.67M-4.49M-73.17M-54.74M-77.39M-67.91M-65.27M487.78M-115.58M-46.95M-79.94M-17.68M37.38M-97.17M
EBITDA Margin-121.91%-63.97%-3636.78%-466.31%-1746.54%-10447.38%-398.68%5614.45%-1385.75%-470.51%-3824.74%-2357.47%866.33%-2042.86%
Net Income-11.05M-4.30M-41.64M-39.39M-48.79M-70.70M-70.66M421.14M5.99M-60.56M-50.35M-65.70M53.51M-112.04M
Net Income Margin-139.36%-61.31%-2069.73%-335.55%-1101.15%-10876.46%-431.61%4847.42%71.75%-606.85%-2409.28%-8759.60%1240.09%-2355.42%
R&D4.23M2.83M2.84M13.41M41.20M71.67M57.29M65.17M61.19M81.52M116.11M96.23M54.28M57.75M
R&D as % of Total Revenue53.30%40.35%140.95%114.21%929.93%11026.46%349.97%750.07%733.56%816.93%5555.65%12831.33%1257.94%1214.14%
Interest Expense609.00K367.00K2.59M835.00K801.00K553.00K392.00K2.64M2.95M4.71M3.95M13.49M10.04M46.74M
Interest Expense % of Total Revenue7.68%5.23%128.93%7.11%18.08%85.08%2.39%30.43%35.32%47.24%189.14%1798.40%232.61%982.55%

Balance Sheet

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets19.18M16.77M228.03M326.75M298.75M339.85M441.76M941.18M989.99M946.01M702.65M693.97M602.63M534.90M
Total Liabilities22.54M24.79M94.34M162.70M206.34M275.85M274.79M290.78M336.45M361.86M155.06M235.74M194.70M229.12M
Total Equity3.09M-884.00K179.00M226.12M177.67M214.30M275.51M668.04M669.75M593.51M542.22M464.07M414.71M312.19M
Cash10.86M7.17M218.96M134.75M62.96M72.65M117.05M132.36M403.88M465.71M149.87M191.08M280.64M254.16M
Total Debt1.46M4.26M6.95M4.96M6.95M7.46M12.37M39.30M76.62M52.75M46.87M25.34M159.14M19.76M
Net Debt-9.40M-2.91M-212.01M-129.80M-56.01M-65.19M-104.68M-93.06M-327.26M-413.68M-102.99M-165.74M-121.50M-234.40M

Cash Flow

Currency: USD2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.45M-8.77M-10.54M-28.61M-58.03M-88.69M-72.80M-98.16M-131.83M-158.27M-178.79M-105.92M-134.37M-86.92M
Investing Cash Flow-200.00K-858.00K747.00K-184.24M-43.23M83.68M-39.65M63.66M364.48M197.38M-107.22M68.99M240.89M64.62M
Financing Cash Flow1.26M5.94M64.72M285.94M29.49M14.70M156.89M49.91M38.87M22.73M-29.83M78.14M-16.96M-6.46M
Capital Expenditure1.45M588.00K420.00K4.61M3.68M2.17M4.49M12.54M5.42M5.66M2.18M245.00K11.00K6.13K
Free Cash Flow-2.90M-9.36M-10.96M-33.22M-61.71M-90.86M-77.29M-110.69M-137.25M-163.94M-180.97M-106.16M-134.38M-86.92M
Dividends Paid136.00K2.00K96.00K--91.00K1.07M112.00K-5.96M4.03M---
FCF to OCF200.07%106.70%103.98%116.11%106.33%102.45%106.17%112.77%104.11%103.58%101.22%100.23%100.01%100.01%
Dividend Paid to FCF-4.68%-0.02%-0.88%---0.10%-1.38%-0.10%--3.63%-2.22%---

Earnings

Report DateApr 7, 2016Sep 7, 2016Apr 5, 2017Sep 5, 2017Apr 12, 2018Aug 28, 2018Apr 24, 2019Apr 9, 2020Aug 27, 2020Apr 15, 2021Aug 24, 2021Apr 26, 2022Aug 28, 2024Apr 30, 2025Aug 28, 2025Sep 22, 2026Apr 29, 2027
EPS Estimate-0.10-0.10-0.10-0.100.00-0.20-0.20-0.20-0.10-0.20-0.15-0.200.000.00---
EPS Actual-0.33-0.13-0.08-0.180.310.000.000.000.000.000.000.00-0.150.39-0.19--
Surprise-230.00%-30.00%20.00%-80.00%-100.00%100.00%100.00%100.00%100.00%100.00%100.00%-----
Timing--------------After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap263.81M
Enterprise Value132.22M
Trailing P/E0.00
Forward P/E14.66
Price / Sales41.45
Price / Book0.98
EPS0.00
Book Value0.9639
Revenue (TTM)6.37M
Gross Profit (TTM)-59.06M
EBITDA-101.25M
Profit Margin33.21%
Operating Margin-1470.37%
Return on Equity0.38%
Return on Assets-10.79%
Shares Outstanding245.18M
Shares Float157.42M
Beta0.81
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%